Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2683

Sort by

Sort Order Select

Journal Articles

Extracellular vesicles shed by follicular lymphoma B cells promote polarization of the bone marrow stromal cell niche

Erwan Dumontet, Céline Pangault, David Roulois, Matthis Desoteux, Simon Léonard, Tony Marchand, Maelle Latour, Patricia Legoix, Damarys Loew, Florent Dingli, Joelle Dulong, Erwan Flecher, Cédric Coulouarn, Guillaume Cartron, Thierry Fest, Karin Tarte

Blood (2021) 138 (1): 57–70.

https://doi.org/10.1182/blood.2020008791

Published: 2021

Includes: Supplemental data

Journal Articles

Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma

Sarah Haebe, Tanaya Shree, Anuja Sathe, Grady Day, Debra K. Czerwinski, Susan M. Grimes, HoJoon Lee, Michael S. Binkley, Steven R. Long, Brock Martin, Hanlee P. Ji, Ronald Levy

Blood (2021) 137 (21): 2869–2880.

https://doi.org/10.1182/blood.2020009855

Published: 2021

Includes: Supplemental data

Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl

Blood (2021) 137 (19): 2634–2645.

https://doi.org/10.1182/blood.2020007512

Published: 2021

Includes: Supplemental data

Journal Articles

Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma

Christopher R. Bolen, Federico Mattiello, Michael Herold, Wolfgang Hiddemann, Sarah Huet, Wolfram Klapper, Robert Marcus, Farheen Mir, Gilles Salles, Oliver Weigert, Tina Nielsen, Mikkel Z. Oestergaard, Jeffrey M. Venstrom

Blood (2021) 137 (19): 2704–2707.

https://doi.org/10.1182/blood.2020008119

Published: 2021

Includes: Supplemental data

Journal Articles

Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma

Paolo Strati, Preetesh Jain, Ralph J. Johnson, Sheryl Forbes, Lei Feng, Felipe Samaniego, Maria A. Rodriguez, Luis E. Fayad, Fredrick Hagemeister, Jason Westin, Michael Wang, Sattva S. Neelapu, Loretta J. Nastoupil, Nathan H. Fowler

Blood (2021) 137 (8): 1124–1129.

https://doi.org/10.1182/blood.2020007994

Published: 2021

Includes: Supplemental data

Journal Articles

Checkpoint blockade in FL: eluding the king

Carla Casulo

Blood (2021) 137 (5): 581–582.

https://doi.org/10.1182/blood.2020008314

Published: 2021

Journal Articles

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma

Philippe Armand, Ann Janssens, Giuseppe Gritti, John Radford, John Timmerman, Antonio Pinto, Santiago Mercadal Vilchez, Peter Johnson, David Cunningham, John P. Leonard, Scott J. Rodig, Patricia Martín-Regueira, Anne Sumbul, Selda Samakoglu, Hao Tang, Stephen M. Ansell

Blood (2021) 137 (5): 637–645.

https://doi.org/10.1182/blood.2019004753

Published: 2021

Includes: Supplemental data

Journal Articles

Long-term limited-stage follicular lymphoma study

Blood (2020) 136 (8): 1013.

https://doi.org/10.1182/blood.2020008382

Published: 2020

Journal Articles

Long-term outcomes for patients with limited-stage follicular lymphoma: update of a population-based study

Andrea C. Lo, Belinda A. Campbell, Tom Pickles, Christina Aquino-Parsons, Laurie H. Sehn, Joseph M. Connors, Kerry J. Savage

Blood (2020) 136 (8): 1006–1010.

https://doi.org/10.1182/blood.2019004588

Published: 2020

Includes: Supplemental data

Journal Articles

Lenalidomide in follicular lymphoma

Christopher R. Flowers, John P. Leonard, Nathan H. Fowler

Blood (2020) 135 (24): 2133–2136.

https://doi.org/10.1182/blood.2019001751

Published: 2020

Journal Articles

Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study

Farheen Mir, Sally F. Barrington, Helen Brown, Tina Nielsen, Deniz Sahin, Michel Meignan, Judith Trotman

Blood (2020) 135 (15): 1214–1218.

https://doi.org/10.1182/blood.2019001091

Published: 2020

Includes: Supplemental data

Journal Articles

CD45-negative follicular lymphoma

Lise Schoonen, Floor Weerkamp

Blood (2020) 135 (11): 879.

https://doi.org/10.1182/blood.2019004694

Published: 2020

Journal Articles

IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution

Mariette Odabashian, Emanuela Carlotti, Shamzah Araf, Jessica Okosun, Filomena Spada, John G. Gribben, Francesco Forconi, Freda K. Stevenson, Mariarita Calaminici, Sergey Krysov

Blood (2020) 135 (11): 834–844.

https://doi.org/10.1182/blood.2019002279

Published: 2020

Includes: Supplemental data

Journal Articles

Localized- and advanced-stage follicular lymphomas differ in their gene expression profiles

Blood (2020) 135 (3): 181–190.

https://doi.org/10.1182/blood.2019000560

Published: 2020

Includes: Supplemental data

Journal Articles

Patient-Reported Disease Burden and Age: Results from a National Patient Advocacy Survey of Patients with Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Keith L. Dawson, DNP, MS, Mark A. Price, MA, MD, Peggy Ann Torney, MS, Victor Gonzalez, MA, MS, Maria Sae-Hau, PhD, Elisa S. Weiss, PhD, Brennan Mange, BA, Carol Mansfield, PhD, Eydith J Comenencia-Ortiz, PhD, Anthony S Masaquel, PhD MPH, Arliene Ravelo, MPH

Blood (2019) 134 (Supplement_1): 4778.

https://doi.org/10.1182/blood-2019-123644

Published: 2019

Journal Articles

Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma

Patrizia Mondello, MD PhD MSc, Angelo Fama, MD, Melissa C Larson, Zhi-Zhang Yang, MD, Jose C Villasboas, Andrew L. Feldman, MD, Susan L Slager, PhD, Brian K. Link, MD, Sergei Syrbu, MD PhD, Anne J Novak, PhD, Thomas M. Habermann, MD, Thomas E. Witzig, MD, Grzegorz Nowakowski, MD, James R. Cerhan, MD PhD, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 121.

https://doi.org/10.1182/blood-2019-126233

Published: 2019

Journal Articles

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

Vindi Jurinovic, PhD, Verena Passerini, PhD, Mikkel Z Oestergaard, PhD, Andrea Knapp, PhD, Kirsten Mundt, PhD, Shamzah Araf, MRCP, MBBS, PhD, Julia Richter, PhD, Jude Fitzgibbon, PhD, Wolfram Klapper, Robert E. Marcus, FRCP, Andrew Davies, MD PhD, Michael Herold, MD, Wolfgang Hiddemann, PhD, Michael Unterhalt, PhD, Eva Hoster, PhD, Oliver Weigert, MD

Blood (2019) 134 (Supplement_1): 122.

https://doi.org/10.1182/blood-2019-130208

Published: 2019

Journal Articles

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Alessandro Pulsoni, MD, Maria Elena Tosti, Statistician, Simone Ferrero, MD, Stefano Luminari, MD, Anna Marina Liberati, Natalia Cenfra, MD, Daniela Renzi, MD, Emanuela Zanni, MD, Carola Boccomini, MD, Andres JM Ferreri, MD, Sara Rattotti, Vittorio Ruggero Zilioli, MD, Patrizia Bernuzzi, MD, Silvia Bolis, MD, Gerardo Musuraca, MD, Luca Nassi, Tommasina Perrone, MD, Caterina Stelitano, MD, Antonella Anastasia, MD, Paolo Corradini, MD, Giovanni Partesotti, MD, Francesca Re, Emanuele Cencini, MD, Clara Mannarella, MD, Donato Mannina, MD, Anna Lia Molinari, MD, Monica Tani, MD, Giorgia Annechini, MD, Giovanni Manfredi Assanto, MD, Lavinia Grapulin, MD, Irene Della Starza, PhD, Marzia Cavalli, PhD, Lucia Anna De Novi, PhD, Elena Ciabatti, Barbara Mantoan, PhD, Anna Guarini, PhD, Luca Arcaini, Umberto Ricardi, MD, Valter Gattei, MD, Sara Galimberti, MD PhD, Marco Ladetto, MD, Ilaria Del Giudice, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 124.

https://doi.org/10.1182/blood-2019-123106

Published: 2019

Journal Articles

Aberrant Cathepsin S Induces a Supportive Immune Microenvironment in Follicular Lymphoma

Blood (2019) 134 (Supplement_1): 657.

https://doi.org/10.1182/blood-2019-122663

Published: 2019

Journal Articles

Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

Franck Morschhauser, MD PhD, Herve Tilly, MD PhD, Aristeidis Chaidos, Tycel J. Phillips, MD, Vincent Ribrag, MD, Philip Campbell, MBBS, FRACP, FRCPA, Damaj Gandhi Laurent, MD PhD, Wojciech Jurczak, MD PhD, Pamela McKay, MD, Stephen Opat, John Radford, Jennifer Whalen, Anand Rajarethinam, Susan Benedict Navia, Deyaa Adib, Gilles Salles, MD PhD

Blood (2019) 134 (Supplement_1): 123.

https://doi.org/10.1182/blood-2019-128096

Published: 2019

NARROW

Extracellular vesicles shed by follicular lymphoma B cells promote polarization of the bone marrow stromal cell niche

Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma

Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma

Checkpoint blockade in FL: eluding the king

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma

Long-term limited-stage follicular lymphoma study

Long-term outcomes for patients with limited-stage follicular lymphoma: update of a population-based study

Lenalidomide in follicular lymphoma

Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study

CD45-negative follicular lymphoma

IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution

Localized- and advanced-stage follicular lymphomas differ in their gene expression profiles

Patient-Reported Disease Burden and Age: Results from a National Patient Advocacy Survey of Patients with Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Aberrant Cathepsin S Induces a Supportive Immune Microenvironment in Follicular Lymphoma

Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only